NCT01949467View on ClinicalTrials.gov

Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 10, 2014

Primary Completion Date

December 19, 2017

Study Completion Date

December 26, 2018

Conditions
Hemochromatosis, Type 4Ferroportin DiseaseDysmetabolic HepatosiderosisDiagnosis
Interventions
DRUG

iron fumarate

All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.

Trial Locations (4)

35000

CHU Pontchaillou, Rennes

Unknown

CHU Clermont-Ferrand, Clermont-Ferrand

CHU Limoges, Limoges

CHU Montpellier, Montpellier

All Listed Sponsors
lead

Rennes University Hospital

OTHER

NCT01949467 - Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. | Biotech Hunter | Biotech Hunter